

ANMC Non-occupational Post-exposure Prophylaxis (nPEP) – Adults and Adolescents

Recommended Populations	Testing before and following nPEP			
<ul style="list-style-type: none"> • Within 72 hours of an isolated incident of high risk HIV exposure, treatment should be initiated as soon as possible • Potential exposures to consider and recommend nPEP: <ul style="list-style-type: none"> ○ Sexual assault ○ Unprotected sex with new partner of unknown HIV status ○ Use or injury with needle or syringe used previously by another person • Not generally recommended for: <ul style="list-style-type: none"> ○ History of sustained active injection drug use (discuss PrEP) ○ Frequent recent high risk sexual exposures (discuss PrEP) 		Baseline	4-6 weeks	4 months
	HIV Ag/Ab	X	X	X
	Hep B surface Ag Hep B surface Ab Hep B core Ab	X		
	Hep C Ab ^a	X		
	Syphilis ^b	X	X	
	Gonorrhea ^b	X		
	Chlamydia ^b	X		
	Pregnancy ^b	X	X	
	Renal Function (Serum Creatinine)	X		
	Liver Function (AST/ALT)	X		
	<p>a – If blood exposure repeat Hepatitis C Ab at 6 months b – If sexual exposure</p>			

Treatment Recommendations

Preferred Regimen		Education
Adults and adolescents ≥13 yo with normal renal function including pregnant females	<ul style="list-style-type: none"> • Tenofovir disoproxil fumarate/Emtricitabine 300mg/200mg PO daily x 28 days PLUS • Dolutegravir 50 mg PO daily x 28 days 	<ul style="list-style-type: none"> • Treatment should not be delayed if waiting on non-rapid HIV Ag/Ab testing results • Follow up with ID, EIS, or Primary Care within 3-5 days for continuation of prescription and arrangement of appropriate follow up plan • Preventive treatment is discontinued after 28 days
Adults and adolescents ≥13 yo with renal dysfunction (CrCl <60 mL/min)	<ul style="list-style-type: none"> • Zidovudine and Lamivudine dose adjust to renal function x 28 days PLUS • Dolutegravir 50 mg PO daily x 28 days 	

ANMC Associated Powerplans: Orders for Sexual Assault Response, AMB HIV and STI Post-exposure Prophylaxis Antimicrobial Stewardship Program Approved April 2023

References: Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. CDC/HHS. Accessed March 4, 2021.